IN.PACT AV access post-approval study: Outcomes from extended cohort “consistent with prior experience”
Extended cohort outcomes from the IN.PACT arteriovenous (AV) access postmarket study were “clinically reasonable and consistent with prior experience”, the 2026 Charing Cross (CX)...
One-year aXess data unlock “new category of vascular access”
“Twelve-month results of the aXess show that the graft is safe to implant, supports early and effective dialysis use, and is associated with...
Innovation meets evidence in CX 2026 vascular access session
What are the best approaches for managing arteriovenous fistula (AVF) stenosis? What role should surveillance play in vascular access management? Is innovation in the...
aXess restorative vascular access conduit gains CE mark
Xeltis has announces that it has received CE mark for aXess, its restorative vascular access conduit for haemodialysis treatment.
The CE mark was granted following...
